See more : HWH International Inc. (HWH) Income Statement Analysis – Financial Results
Complete financial analysis of Impel Pharmaceuticals Inc. (IMPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Impel Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) Income Statement Analysis – Financial Results
- Naksh Precious Metals Limited (NAKSH.BO) Income Statement Analysis – Financial Results
- Tokyo Koki Co. Ltd. (7719.T) Income Statement Analysis – Financial Results
- Commonwealth Bank of Australia (CBAUF) Income Statement Analysis – Financial Results
- SUDARSHAN PHARMA INDUSTRIES LI (SUDARSHAN.BO) Income Statement Analysis – Financial Results
Impel Pharmaceuticals Inc. (IMPL)
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.65M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 6.50M | 691.00K | 0.00 | 0.00 |
| Gross Profit | 6.16M | -23.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.66% | -3.44% | 0.00% | 0.00% |
| Research & Development | 11.46M | 20.56M | 27.29M | 28.81M |
| General & Administrative | 77.89M | 50.90M | 18.05M | 12.75M |
| Selling & Marketing | 7.60M | 12.60M | 0.00 | 0.00 |
| SG&A | 77.89M | 50.90M | 18.05M | 12.75M |
| Other Expenses | -9.29M | -5.05M | -408.00K | -680.00K |
| Operating Expenses | 89.34M | 71.46M | 45.33M | 41.57M |
| Cost & Expenses | 95.84M | 72.15M | 45.33M | 41.57M |
| Interest Income | 10.58M | 2.25M | 0.00 | 417.00K |
| Interest Expense | 13.84M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.20M | 1.09M | 1.08M | 722.00K |
| EBITDA | -83.18M | -70.40M | -44.26M | -40.84M |
| EBITDA Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Operating Income | -83.18M | -71.49M | -45.33M | -41.57M |
| Operating Income Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.13M | -5.05M | -463.00K | -263.00K |
| Income Before Tax | -106.31M | -76.53M | -45.80M | -41.83M |
| Income Before Tax Ratio | -840.28% | -11,457.19% | 0.00% | 0.00% |
| Income Tax Expense | 23.13M | 2.00K | 1.00K | 30.00K |
| Net Income | -129.44M | -76.54M | -45.80M | -41.86M |
| Net Income Ratio | -1,023.08% | -11,457.49% | 0.00% | 0.00% |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23.45M | 14.60M | 13.14M | 13.14M |
| Weighted Avg Shares Out (Dil) | 23.45M | 14.60M | 13.14M | 13.14M |
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
Impel NeuroPharma, Inc. (IMPL) CEO Adrian Adams on Q1 2022 Results - Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports